ICON Public (NASDAQ:ICLR) Reaches New 12-Month High at $263.20

ICON Public Limited (NASDAQ:ICLR)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $263.20 and last traded at $263.17, with a volume of 63062 shares changing hands. The stock had previously closed at $260.23.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ICLR. Mizuho upped their price objective on shares of ICON Public from $250.00 to $274.00 in a research report on Tuesday, July 11th. StockNews.com assumed coverage on ICON Public in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft increased their price target on ICON Public from $280.00 to $300.00 in a research note on Friday, July 14th. Finally, Barclays upped their target price on ICON Public from $250.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $265.22.

ICON Public Stock Performance

The firm’s 50 day simple moving average is $247.00 and its 200-day simple moving average is $225.31. The company has a market capitalization of $21.59 billion, a price-to-earnings ratio of 42.31, a P/E/G ratio of 1.46 and a beta of 1.13. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.22 and a current ratio of 1.22.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.04. ICON Public had a return on equity of 11.21% and a net margin of 6.45%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.02 billion. Analysts expect that ICON Public Limited will post 12.06 EPS for the current year.

Institutional Investors Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Laurel Wealth Advisors Inc. increased its stake in shares of ICON Public by 2.0% during the 1st quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock worth $658,000 after purchasing an additional 54 shares during the last quarter. KB Financial Partners LLC increased its holdings in shares of ICON Public by 23.4% during the 1st quarter. KB Financial Partners LLC now owns 1,742 shares of the medical research company’s stock valued at $424,000 after acquiring an additional 330 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of ICON Public by 4.8% in the 2nd quarter. Captrust Financial Advisors now owns 28,338 shares of the medical research company’s stock valued at $6,141,000 after acquiring an additional 1,296 shares in the last quarter. Alpha Paradigm Partners LLC acquired a new stake in ICON Public in the 3rd quarter worth approximately $123,000. Finally, Handelsbanken Fonder AB boosted its position in ICON Public by 1.2% during the fourth quarter. Handelsbanken Fonder AB now owns 8,330 shares of the medical research company’s stock worth $1,618,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.